mounjaro eli lilly - Search News

Eli Lilly threatens Zepbound copycat makers

Eli Lilly sues two pharmacies making copycat Zepbound, Mounjaro

Eli Lilly is suing Strive Pharmacy and Empower Pharmacy for compounding tirzepatide, the active ingredient in Zepbound and Mounjaro.

Free Press Journal on MSN · 8d

Mounjaro: Here Is How Eli Lilly Shares Have Performed Since The Launch Its Own 'Ozempic'

Ozempic, the Danish pharma giant Novo Nordisk's anti-diabetic drug, has had everyone's attention over the past year. The injectable drug clinically known as semaglutide has made major promises, including the immense potential to fight obesity and other major conditions.

Business Insider · 2d

Eli Lilly threatens Zepbound copycat makers after shortage, Bloomberg reports

Eli Lilly (LLY) is targeting additional drug compounders and telehealth companies that make copycat versions of its weight loss drug, with

Hims, Eli Lilly

Fierce Healthcare · 2h

DTC obesity med market heats up: Eli Lilly taps knownwell, Hims & Hers adds new weight loss meds to platform

Hims & Hers is expanding access to Eli Lilly's branded weight loss drug Zepbound and diabetes drug Mounjaro as well as generics of Novo Nordisk's diabetes drug liraglutide through its weight loss platform.

Investopedia on MSN · 1d

Hims & Hers Stock Surges as Telehealth Platform Adds Eli Lilly Weight-Loss Drugs

Hims & Hers Health shares jumped Tuesday as the company added Eli Lilly’s weight-loss drug Zepbound and diabetes treatment Mounjaro to its telehealth platform.

Reuters on MSN · 1d

Hims & Hers to sell Lilly's weight-loss drug on its telehealth platform

Telehealth firm Hims & Hers Health said on Tuesday it plans to sell Eli Lilly's weight-loss drug, as it widens its offerings to offset any impact from impending restrictions on se

13don MSN

Eli Lilly launches weight-loss drug Mounjaro in India, beats Novo Nordisk to major market

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

2don MSN

Eli Lilly sues Strive and Empower as FDA lifts tirzepatide shortage status

Eli Lilly sues two compounders over tirzepatide after FDA lifts Zepbound, Mounjaro shortage status in key GLP-1 legal test.

2don MSN

Where Will Eli Lilly Be in 1 Year?

Lately, however, Eli Lilly's stock has cooled. Shares have been essentially flat since July 2024. The market for GLP-1 ...

Live Mint on MSN13d

Mounjaro hits shelves in India: How Eli Lilly’s weight loss drug compares with Ozempic — price, side effects and more

Eli Lilly launches Mounjaro, the much-awaited diabetes drug, in India. It is priced at ₹3,500 for 2.5 mg. Mounjaro and ...

Eli Lilly Sues Two Firms Alleging Copycat Tactics

Eli Lilly (NYSE:LLY) shares dropped in price Wednesday, amid news the company is suing two pharmacies for compounding Zepbound and Mounjaro. Lilly claims the companies are skirting the Food and Drug ...

1don MSN

Eli Lilly weight loss therapy added to Hims & Hers platform (update)

Hims & Hers Health (NYSE:HIMS) stock gains as the company adds Eli Lilly's (LLY) weight loss therapy tirzepatide & generic ...

1don MSN

Hims & Hers to sell Lilly's Zepbound on its telehealth platform

Telehealth firm Hims & Hers Health said on Monday it plans to sell Eli Lilly's diabetes and weight-loss drugs on its platform ...

1don MSN

Eli Lilly and Company (LLY): The Best Healthcare Stock to Buy According to Billionaires

We recently published a list of 10 Best Healthcare Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results